Sears, Cynthia L
Pardoll, Drew M
Article History
First Online: 6 March 2018
Competing interests
: D.M.P. receives funding from Bristol–Myers Squibb and the Melanoma Research Alliance for immunotherapy research and consults for a number of companies with interests in immunotherapy, namely Compugen, GlaxoSmithKline, Medimmune/AstraZeneca, Merck, Potenza Therapeutics, Sanofi, Tizona, DNatrix, Amgen, Rock Springs Capital, Immunomic Therapeutics, Janssen, WindMil Therapeutics and Bayer. D.M.P. and C.L.S. are both supported by the Bloomberg-Kimmel Institute for Immunotherapy.